scholarly journals MON-LB073 The Serum Creatinine to Serum Cystatin C Ratio Is a Reliable Surrogate Marker of Sarcopenia in Patients with Cushing's Syndrome in Remission

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Luciana Martel ◽  
Helena Bascuñana ◽  
Alicia Alonso ◽  
Jordi Diaz-Manera ◽  
Jaume Llauger ◽  
...  
Keyword(s):  
Serum Creatinine ◽  
Cystatin C ◽  
Cushing’S Syndrome ◽  
Surrogate Marker ◽  
Cushing's Syndrome ◽  
Serum Cystatin C ◽  
Serum Cystatin

The Ratio Serum Creatinine/Serum Cystatin C (a Surrogate Marker of Muscle Mass) as a Predictor of Hospitalization in Chronic Obstructive Pulmonary Disease Outpatients

Respiration ◽  
2018 ◽  
Vol 97 (4) ◽  
pp. 302-309 ◽  
Author(s):  
Carlos Antonio Amado ◽  
Maria Teresa García-Unzueta ◽  
Bernardo Alio Lavin ◽  
Armando Raúl Guerra ◽  
Juan Agüero ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Serum Creatinine ◽  
Pulmonary Disease ◽  
Muscle Mass ◽  
Cystatin C ◽  
Surrogate Marker ◽  
Chronic Obstructive ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Obstructive Pulmonary Disease

scholarly journals P60 Serum Creatinine is superior to Serum Cystatin C in explaining inter-individual variability of vancomycin clearance in neonates and young infants

2019 ◽  
Vol 104 (6) ◽  
pp. e42.1-e42
Author(s):  
S Leroux ◽  
V Biran ◽  
J van den Anker ◽  
W Zhao ◽  
E Jacqz-Aigrain ◽  
...  
Keyword(s):  
Serum Creatinine ◽  
Cystatin C ◽  
Neonatal Intensive Care ◽  
Surrogate Marker ◽  
Compartment Model ◽  
Individual Variability ◽  
Therapeutic Drug ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Young Infants

BackgroundSerum creatinine (SCr) is used as a surrogate marker of glomerular filtration rate to guide dosing of drugs eliminated by the kidney. Serum Cystatin C (S-CysC) has been suggested as a more reliable biomarker than SCr for monitoring kidney function in adults and children. Purpose of this study was to evaluate whether S-CysC is a more useful marker for estimating vancomycin clearance in neonates and young infants.MethodsPharmacokinetic (PK), Scr and S-CysC data were collected in patients undergoing continuous intravenous vancomycin treatment in the neonatal intensive care unit of Robert Debré Hospital - Paris. A population PK analysis was performed with the software package NONMEM, utilizing vancomycin therapeutic drug monitoring samples. S-CysC and SCr were compared in terms of usefulness to explain inter-individual variability (IIV) of vancomycin clearance. Statistical criteria were used for covariate selection.ResultsA total of 58 concentrations from 47 patients (gestational age [GA] ranging from 23 to 41 weeks and postmenstrual age [PMA] ranging from 26 to 46 weeks) were modeled with an allometric one-compartment model with first-order elimination. The median (range) values for SCr and S-CysC were 41.5 (12.0 to 102.0) µmol/L and 1.38 (0.95 to 2.32) mg/L, respectively. When tested individually, SCr and S-CysC explained 26.4% and 9.8% of IIV of vancomycin clearance, respectively. PMA was superior as a covariate on clearance, over the combination of GA and postnatal age. As such, bodyweight, PMA, and SCr were retained as significant covariates on clearance in the final model.ConclusionsSerum Creatinine was found to be more useful than Serum Cystatin C to explain IIV of vancomycin clearance in this population. Further studies are needed to evaluate the utility of renal biomarkers to predict clearance and dosing of renally eliminated drugs in neonates.Disclosure(s)Nothing to disclose

scholarly journals Cystatin C for estimation of glomerular filtration rate in patients with spinal cord injury

2003 ◽  
Vol 40 (4) ◽  
pp. 364-368 ◽  
Author(s):  
Margaret A. Jenkins ◽  
Douglas J. Brown ◽  
Francesco L. Ierino ◽  
Sujiva I. Ratnaike
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Serum Creatinine ◽  
Creatinine Clearance ◽  
Cystatin C ◽  
Filtration Rate ◽  
Surrogate Marker ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Cord Injury

Background: Serum creatinine is not a satisfactory marker of glomerular filtration rate (GFR) in patients with spinal cord injury (SCI) who have varying degrees of muscle atrophy. In contrast to serum creatinine, serum cystatin C, a 13-kDa protein, is not affected by muscle mass and is therefore potentially a useful marker of GFR in patients with SCI. In addition, cystatin C is not dependent on sex or age and is not secreted by the renal tubule. Aim: We assessed serum cystatin C as a surrogate marker of GFR in SCI patients. Methods: Cystatin C was analysed using a particle-enhanced immunonephelometric assay (Dade Behring) in serum samples sent for routine measurement of creatinine (64 patients) and creatinine clearance (27 patients) from patients in the Spinal Unit of the Austin Health. We compared these results with serum cystatin C of 57 non-SCI patients who had had a creatinine clearance measurement during the study period. Results: In patients with SCI, the reciprocal of cystatin C had a stronger correlation (r = 0·48, P<0·01) with creatinine clearance than the reciprocal of serum creatinine (r = 0·25, P<0·19). Further, the value of serum creatinine was much lower for a given creatinine clearance in SCI patients than in non-SCI patients; the serum cystatin C concentrations were equivalent. Conclusion: The serum cystatin C is a convenient and more reliable surrogate marker of GFR than serum creatinine and will enable early detection of renal impairment. We need to confirm this finding with a larger study, including comparison with an accepted gold standard for GFR.

scholarly journals Reference intervals for serum cystatin C and serum creatinine in an adult sub-Saharan African population

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Bertille Elodie Edinga-Melenge ◽  
Adrienne Tchapmi Yakam ◽  
Jobert Richie Nansseu ◽  
Catherine Bilong ◽  
Suzanne Belinga ◽  
...  
Keyword(s):  
Serum Creatinine ◽  
Cystatin C ◽  
Reference Intervals ◽  
African Population ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Sub Saharan

scholarly journals Comparison of estimated GFR equations based on serum cystatin C alone and in combination with serum creatinine in patients with coronary artery disease

2015 ◽  
Vol 15 (7) ◽  
pp. 571-576 ◽  
Author(s):  
Yusuf Cetin Doganer ◽  
Umit Aydogan ◽  
James Edwin Rohrer ◽  
Aydogan Aydogdu ◽  
Tuncer Cayci ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Serum Creatinine ◽  
Cystatin C ◽  
Serum Cystatin C ◽  
Estimated Gfr ◽  
Serum Cystatin ◽  
Artery Disease

scholarly journals Improved Prediction of Decreased Creatinine Clearance by Serum Cystatin C: Use in Cancer Patients before and during Chemotherapy

2000 ◽  
Vol 46 (2) ◽  
pp. 193-197 ◽  
Author(s):  
Borut Štabuc ◽  
Levin Vrhovec ◽  
Mirna Štabuc-Šilih ◽  
Tomaž Edvard Cizej
Keyword(s):  
Serum Creatinine ◽  
Creatinine Clearance ◽  
Cancer Patients ◽  
Cystatin C ◽  
Stepwise Regression ◽  
Roc Analysis ◽  
Cysteine Protease Inhibitor ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Turbidimetric Immunoassay

Abstract Background: Serum cystatin C, a cysteine protease inhibitor, has been suggested as a new marker of glomerular filtration rate (GFR). This study explored the possibility of replacing the creatinine clearance (CrCl) estimation of GFR with cystatin C in early detection of renal impairment in cancer patients on chemotherapy. Methods: Serum creatinine and cystatin C concentrations as well as 24-h CrCl were determined simultaneously in 72 cancer patients. Among them, 60 were treated with combined chemotherapy with cisplatin (CDDP). Creatinine was determined enzymatically with a spectrophotometric method. Serum cystatin C was determined by a particle-enhanced turbidimetric immunoassay. Results: Cystatin C and creatinine correlated significantly (P = 0.001) with CrCl. The correlation was significantly better for cystatin C than creatinine (r = 0.84 vs 0.74; P = 0.01). Stepwise regression analysis identified no differences for the correlations between cystatin C and CrCl in patients with or without metastases (r = 0.82 and 0.84, respectively) as well as before treatment and before the fourth cycle of chemotherapy (r = 0.70 and 0.75, respectively). A cystatin C cutoff concentration of 1.33 mg/L had 87% sensitivity and 100% specificity for detecting CrCl &lt;78 mL/min. ROC analysis indicated that cystatin C was superior to serum creatinine for predicting CrCl &lt;78 mL/min (P &lt;0.04). Conclusions: Serum cystatin C is superior to serum creatinine for detection of decreased CrCl and potentially for the estimation of GFR in cancer patients independent of the presence of metastases or chemotherapy.

scholarly journals Comparison of serum creatinine and serum cystatin C as biomarkers to detect sepsis-induced acute kidney injury and to predict mortality in CD-1 mice

2014 ◽  
Vol 307 (8) ◽  
pp. F939-F948 ◽  
Author(s):  
Asada Leelahavanichkul ◽  
Ana Carolina P. Souza ◽  
Jonathan M. Street ◽  
Victor Hsu ◽  
Takayuki Tsuji ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Serum Creatinine ◽  
Cystatin C ◽  
Cecal Ligation ◽  
Kidney Injury ◽  
Organ Damage ◽  
Experimental Sepsis ◽  
Sepsis Mortality ◽  
Serum Cystatin C ◽  
Serum Cystatin

Acute kidney injury (AKI) dramatically increases sepsis mortality, but AKI diagnosis is delayed when based on serum creatinine (SCr) changes, due in part, to decreased creatinine production. During experimental sepsis, we compared serum cystatin C (sCysC), SCr, and blood urea nitrogen (BUN) to inulin glomerular filtration rate (iGFR) before or 3–18 h after cecal ligation and puncture (CLP)-induced sepsis in CD-1 mice. sCysC had a faster increase and reached peak levels more rapidly than SCr in both sepsis and bilateral nephrectomy (BiNx) models. sCysC was a better surrogate of iGFR than SCr during sepsis. Combining sCysC with SCr values into a composite biomarker improved correlation with iGFR better than any biomarker alone or any other combination. We determined the renal contribution to sCysC handling with BiNx. sCysC and SCr were lower post-BiNx/CLP than post-BiNx alone, despite increased inflammatory and nonrenal organ damage biomarkers. Sepsis decreased CysC production in nephrectomized mice without changing body weight or CysC space. Sepsis decreased sCysC production and increased nonrenal clearance, similar to effects of sepsis on SCr. sCysC, SCr, and BUN were measured 6 h postsepsis to link AKI with mortality. Mice with above-median sCysC, BUN, or SCr values 6 h postsepsis died earlier than mice with below-median values, corresponding to a substantial AKI association with sepsis mortality in this model. sCysC performs similarly to SCr in classifying mice at risk for early mortality. We conclude that sCysC detects AKI early and better reflects iGFR in CLP-induced sepsis. This study shows that renal biomarkers need to be evaluated in specific contexts.

Sign in / Sign up

Export Citation Format

Share Document